Effect of immunosuppression maintenance in solid organ transplant recipients with COVID-19: Systematic review and meta-analysis

Arta Karruli1 | Serenella Spiezia1 | Filomena Boccia1 | Massimo Gagliardi1 | Fabian Patauner1 | Anna Salemme1 | Ciro Maiello3 | Rosa Zampino1,2 | Emanuele Durante-Mangoni1,2

Abstract

Background: The aim of this study was to assess the effect of continuing immune suppressive therapy in solid organ transplant recipients (SOTR) with coronavirus disease 2019 (COVID-19).

Methods: Systematic review and meta-analysis of data on 202 SOTR with COVID-19, published as case reports or case series. We extracted clinical, hematological, imaging, treatment, and outcome data.

Results: Most patients were kidney recipients (61.9%), males (68.8%), with median age of 57 years. The majority was on tacrolimus (73.5%) and mycophenolate (65.8%). Mortality was 18.8%, but an equal proportion was still hospitalized at last follow up. Immune suppressive therapy was withheld in 77.2% of patients, either partially or completely. Tacrolimus was continued in 50%. One third of survivors that continued immunosuppressants were on dual therapy plus steroids. None of those who continued immunosuppressants developed critical COVID-19 disease. Age (OR 1.07, 95% CI 1.1-1.11, \( P = .001 \)) and lopinavir/ritonavir use (OR 3.3, 95%CI 1.2-8.5, \( P = .013 \)) were independent predictors of mortality while immunosuppression maintenance (OR 0.067, 95% CI 0.008-0.558, \( P = .012 \)) and tacrolimus continuation (OR 0.3, 95% CI 0.1-0.7, \( P = .013 \)) were independent predictors of survival.

Conclusions: Our data suggest that maintaining immune suppression might be safe in SOTR with moderate and severe COVID-19. Specifically, receiving tacrolimus could be beneficial for COVID-19 SOTR. Because of the quality of the available evidence, no definitive guidance on how to manage SOTR with COVID-19 can be derived from our data.

KEYWORDS

COVID-19, immune suppression, outcome, solid organ transplant recipient, tacrolimus

Abbreviations: ACE2, angiotensin converting enzyme 2; ALT, alanine transaminase; ARDS, acute respiratory distress syndrome; AST, aspartate transaminase; CI, confidence interval; CNI, calcineurin inhibitors; COVID-19, Coronavirus Disease 2019; CRP, C-reactive protein; CT, computed tomography; F, female; ICU, intensive care unit; IL2r, interleukin-2 receptor; IL6, interleukin-6; IL7, interleukin-7; IQR, interquartile range; LDH, lactate dehydrogenase; M, male; mTOR, mammalian target of rapamycin; NIV, non invasive ventilation; OR, odds ratio; PRISMA, preferred reporting items for systematic reviews and meta-analyses; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; SOTR, solid organ transplant recipient; SPSS, statistical package for social sciences.
1 | INTRODUCTION

The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in China in 2019 and rapidly spread worldwide causing the new disease named Coronavirus Disease 2019 (COVID-19). Mechanisms of pathogenicity of SARS-CoV-2 have yet to be fully understood. In a review by Saddqui and Mehra, a three stage classification of COVID-19 clinical course, regardless of the baseline immune state, has been proposed. Stage 1 spans from inoculation to initial clinical symptoms. Following viral attachment to the ACE2 receptors, located in the lung, small intestine epithelium, and vascular endothelium, primary manifestations are respiratory, gastrointestinal and systemic. During this phase, lymphopenia may ensue. Stage 2 is characterized by pulmonary involvement because of both direct viral effects and virus-triggered inflammation. Laboratory exams usually reveal lymphopenia, altered hepatic function, and lung computed tomography shows lung infiltrates. Hypoxia may already be present. Stage 3 is characterized by the rapid establishment of an excessive immune response generating a systemic hyper-inflammation syndrome, with major increase of inflammatory cytokines and biomarkers such as C-reactive protein (CRP), IL6, IL2r, IL7, ferritin, and D-dimer. High levels of inflammatory cytokines and biomarkers correlate with a higher score of lung involvement on CT scan. Lung CT scan score can be used to identify severe cases, and the inflammatory storm and hypercoagulability can indicate a higher risk of progressing to multiorgan failure and death.

Being a viral illness, COVID-19 could have a more complicated course in immunosuppressed hosts. However, the important role of the immune response in the late stages of the disease raises the question as to whether immune suppression could actually be protective in terms of disease progression. On the other hand, immune suppression could hamper or delay viral control generating a more prolonged immune stimulation, translating into a more severe clinical course and a higher chance of a negative outcome.

At present, COVID-19 clinical course and outcome in immune compromised patients, including solid organ transplant recipients (SOTR), seems to be grim, with mortality ranging between 20% and 30%. Interestingly, most data published so far show the majority of SOTR with COVID-19 have either partially or completely withdrawn immune suppressive therapy. In an attempt to improve our understanding of the effects of ongoing immune suppressive therapy in COVID-19 SOTR, we performed a systematic literature review. We aimed to describe in better detail the clinical features and the outcome of COVID-19 in SOTR, with a specific focus on the effects of immune suppression changes.

2 | METHODS

2.1 | Study identification

This study is an individual patient data meta-analysis of SOTR with COVID-19. Publications in any form, including conference presentations, journal articles and non-peer-reviewed advance access publications, reporting data on SOTR with COVID-19, from January 1, 2020 to July 12 2020 were searched through PubMed, OVID, and Google Scholar. The search terms included “COVID-19,” “transplant,” “solid organ recipient,” “SARS-CoV-2 infection.”

2.2 | Study selection

Articles were included in our analysis if they provided information about every patient ≥18 years old and not presented in a collective manner but as single patient data. Thus, case reports and case series, regardless of the number of patients described, which provided information about each included case, were used. Articles were scrutinized for data retrieval and corresponding authors were contacted in order to obtain missing information if a specific information was not included in their article.

All relevant publications were used, irrespective of origin and type of article. While we searched for studies regardless of their language, only studies reported in English were included.

2.3 | Study and data extraction

Two investigators selected articles, evaluated the quality of the studies selected and entered findings independently into a database using data provided in figures, tables, and text. In case of disagreement, each case was discussed and controversy resolved through debate and mutual consensus. We ensured no overlapping data were used by giving a unique ID to each case included in the dataset.

2.4 | Inclusion/exclusion criteria

All SOTR patients ≥18 years old with confirmed SARS-CoV-2 infection through nasopharyngeal/oropharyngeal swab.

Non solid organ transplant recipients and patients younger than 18 years were excluded.

2.5 | Variables analyzed

For each patient, we extracted general clinical data, hematological parameters, chest imaging results, treatments received and disease outcome. Among the clinical data we sought, there were: age, sex; organ transplanted; immune suppressive regimens used; symptoms at onset of COVID-19; timing of COVID-19 relative to transplant; interval from symptom onset to hospital admission; comorbidities. Hemato-chemical parameters considered were blood cell count and differential, lactate dehydrogenase, C-reactive protein, procalcitonin, creatinine, alanine/aspartate aminotransferases (ALT/AST), D-dimer, ferritin, interleukin-6, tacrolimus plasma levels.
Presence of chest CT abnormalities compatible with COVID-19 was noted. A detailed analysis of immune suppressing agents used at onset and their handling during the disease course was performed. We also extracted and analyzed data on antiviral and/or immune modulating agent administration. Clinical classification was based on the worst clinical stage the patient progressed to. Accordingly, cases were classified in mild, moderate, severe and critical disease according to WHO guidelines. Mild disease was defined as symptomatic patients meeting the case definition for COVID-19 without evidence of viral pneumonia or hypoxia; moderate disease as pneumonia without respiratory failure; severe disease as severe pneumonia with respiratory failure and oxygen saturation <90%; and critical disease as acute respiratory distress syndrome (ARDS). Predefined outcome considered was patient death.

2.6 | Statistical analysis

Most analyses were performed on data obtained at the time of admission. Numerical variables were presented as median and interquartile range (IQR), while categorical variables as number and percentage. The statistical significance of differences was evaluated by chi-square or Fisher’s exact test for categorical variables and by Mann-Whitney U test for numerical variables. Items associated to outcomes at univariate analysis (P < .05) were included in a multivariate logistic regression model to identify covariates independently associated with the outcome of interest. All analyses were carried out with the aid of SPSS 25 (IBM, Armonk, NY, USA) with the assumption of a P-value ≤ .05 as indicative of statistical significance of the observed differences and using two-sided tests.

3 | RESULTS

The literature search identified 790 articles. After exclusion of articles not regarding COVID-19 in SOTR, or articles regarding opinions, different protocols, or concerns about COVID-19 in SOTR, we identified 88 unique papers regarding COVID-19 in SOTR, including case reports, single- or multi-center studies irrespective of whether presenting information in a collective or single patient manner. Subsequently, after a full text review, we included in our analysis a total of 201 SOTR with COVID-19 from 67 articles that met the inclusion criteria plus 1 case, a kidney transplant recipient admitted to our hospital. All articles except one (which was a preprint) were journal articles. The flow diagram of the literature search with exclusion criteria is presented in Figure 1 according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement.

Clinical features of SOTR with COVID-19 are shown in Table 1. SOTR with COVID-19 were mostly males (139 of 202, 68.8%), median age of 57 years. Most were kidney transplant recipients (61.9%), with a prior history of hypertension. Patients had a long median transplant history, 77 months. In terms of symptoms, most patients had fever (79.7%) and 93% were hospitalized as inpatients. Despite the short time between symptom onset and admission (median 4 days), most patients (85.7%) had an abnormal
finding on CT scan at hospitalization. On the other hand, 23 cases (11.3%) had a negative initial CT scan (Table 1). Most had normal white blood cell count on hospital admission (115 patients, median 5460, IQR 4000-7800 cells/mL), lymphopenia (108 patients, median 651, IQR 420-1107 cells/mL), elevated LDH (45 patients, median 340, IQR 271-511 U/L), high C-reactive protein (39 patients, median 50, IQR 27-116 mg/L), increased d-dimer (32 patients, median 1057, IQR 641-2018 ng/mL), high ferritin (31 patients, median 593, IQR 221-1156 ng/mL) and elevated IL-6 (21 patients, median 58, IQR 21-124 pg/mL). As most study patients were kidney transplant recipients, immune suppressors were modified in most cases (77.2%), either partially (43.7%) or completely withheld (33.5%). Tacrolimus was maintained in 50% of cases. Mycophenolate was maintained unchanged in 27 patients (13.5%) and reduced in 7 patients (3.5%). Most COVID-19 SOTR progressed toward respiratory failure (61.3%), which was treated with noninvasive ventilation in 59% and with invasive mechanical ventilation in 25% of cases.
The majority of patients were on a tacrolimus and mycophenolate regimen (Table 1). As intensity of immune suppression varies according to transplant age, we compared clinical features of SOTR according to transplant duration.

As shown in Table S1, COVID-19 outcome was not different in recipients grouped according to transplant duration, although differences were observed. Recently transplanted patients were younger \( (P = 0.023) \). The proportion of patients receiving tacrolimus \( (P < 0.001) \), and steroids \( (P = 0.032) \) was higher among those more recently transplanted and the opposite occurred for cyclosporin A \( (P = 0.001) \). There were no differences in terms of COVID-19 treatment between the two groups.

Definitive cure, defined as discharge to home after hospitalization and/or no need for further COVID-19 treatment for hospitalized or nonhospitalized patients, was reported in 61.4% of cases. Reported mortality was 18.8%, while 18.8% patients were still in hospital at the latest follow up and in 1% outcome was not specified. After excluding patients who were still hospitalized at the time of the report and those with unspecified outcome, we performed an analysis of factors associated with hospital mortality in 162 SOTR with COVID-19 (Table 2). An older age \( (P < 0.001) \), higher WBC, yet in the normal range \( (P = 0.035) \), higher LDH, IL-6, ferritin \( (P = 0.004, P = 0.002, P = 0.006) \) along with presence of respiratory symptoms \( (P = 0.016) \), presence of abnormal lung CT scan at hospitalization \( (P = 0.024) \), and treatment with lopinavir or darunavir regimens \( (P < 0.001, P = 0.038) \), invasive ventilation therapy \( (P = 0.000) \) were associated with a higher risk of mortality, while maintenance of previous immune suppression \( (P < 0.001) \) and ongoing treatment with tacrolimus \( (P < 0.001) \) were protective in terms of mortality. We then included in a multivariate analysis the four variables more strongly associated with mortality on the univariate analysis. Age \( (OR 1.07, 95\% CI 1.01-1.11, P = 0.001) \) and treatment with a lopinavir-based regimen \( (OR 3.3, 95\% CI 1.2-8.5, P = 0.013) \) were independent predictors of mortality while no change to the immune suppression therapy \( (OR 0.067, 95\% CI 0.008-0.558, P = 0.012) \) and continuation of tacrolimus \( (OR 0.3, 95\% CI 0.1-0.7, P = 0.013) \) were independent predictors of survival (Table 2).

Comparison of patients who did not change their immune suppression therapy with those that changed their therapy either partially or completely is presented in Table 3. The group that underwent changes to their immune suppression did not have more comorbidities but had a higher rate of hypertension \( (P = 0.001) \), a higher prevalence of mycophenolate \( (P = 0.001) \) and steroid treatment \( (P = 0.003) \), and had higher white blood cell count \( (P = 0.011) \), LDH \( (P = 0.028) \), and creatinine \( (P = 0.008) \). Also, these subjects had more often symptoms such as fever \( (P < 0.001) \) and pulmonary imaging positivity on diagnosis \( (P < 0.001) \), although lymphopenia was seen in both groups and respiratory symptoms, fever and abnormal pulmonary imaging were seen in more than 50% of cases continuing immune suppressive treatment. In the group that continued previous immune suppression, the worst COVID-19 disease stages observed were moderate and severe (33.3% and 35.8%). In contrast, most patients who underwent changes in their immune suppressive regimen progressed to severe and critical disease (45.4% and 35.6%) \( (P < 0.001 \) for comparison, Table 3).

In survivors who did not change regimen, 33.3% received dual therapy plus steroids, 12.8% dual therapy without steroids, 17.9% dual therapy including steroids and 35.8% received one drug (Table S2). Only 1 patient on dual therapy plus steroid died.

Sparse data were available regarding bacterial coinfection during hospitalization. Also, no information was found regarding thromboembolic complications.

Comparing patients that continued tacrolimus with those who withdrew it or did not receive any tacrolimus (Table 4), no differences were seen in terms of general comorbidities, although those who continued had more diabetes \( (P = 0.003) \), shorter transplant duration \( (P < 0.001) \), higher LDH \( (P = 0.015) \), lower CRP \( (P = 0.025) \), and lower creatinine \( (P = 0.022) \). They also had lower rates of fever and abnormal pulmonary imaging at diagnosis \( (P = 0.014, P = 0.019) \), although more than 70% of them were symptomatic and with positivity to imaging and 36% needed invasive ventilation. In the two groups, the worst COVID-19 disease was severe (42.3% no tacrolimus vs 46.5% tacrolimus), although critical patients were mostly observed in the tacrolimus withdrawal/no tacrolimus group (40% vs 14.7%).

In both groups the withdrawal of immune suppressive treatment and/or tacrolimus was associated with a greater use of steroids, lopinavir, and anti-interleukin-6 treatment.

Mycophenolate was continued in 34 patients (17%). Comparing patients that continued with those who withdrew or did not receive mycophenolate (Table 5), no differences were seen in terms of comorbidities and symptoms at diagnosis. However, patients treated with mycophenolate had lower LDH \( (P = 0.020) \), lower rates of hydroxychloroquine \( (P = 0.003) \), steroid \( (P = 0.016) \), and anti-IL-6 treatment \( (P = 0.050) \), and a better survival \( (P = 0.028) \). The rate of de novo steroid treatment was 7.8% in those who withdrew mycophenolate and 5.8% in those who did not \( (P = 1.000) \).

No differences in terms of outcome was seen between groups that continued only calcineurin inhibitors (CNI), only mycophenolate or both (Table S3).

4 | DISCUSSION

Our results suggest that COVID-19 in SOTR has a high mortality rate (18.8%). This figure might be underestimated, considering up to 18.8% of studied patients were still in hospital or on outpatient follow up without a definitive outcome. This mortality is higher than that seen in the overall population infected with COVID-19 (about 1.4%-7.2%)26-79 compares to the mortality observed in COVID-19 ICU patients (25%)80 and is in line with other studies on SOTR with COVID-19 (20%-30%).8-10 However, information about median follow up time was not available in most cases, a limitation of our dataset.

In most initial studies on SOTR with COVID-19, immune suppressors were withheld partially or completely in most cases. Our
| Parameter                        | Outcome                               | Univariate analysis | Multivariate analysis |
|---------------------------------|---------------------------------------|---------------------|-----------------------|
|                                 | Survived (N = 124) | Deceased (N = 38)  | OR 95% CI | P value | OR 95% CI | P value |
| Type of transplant              |                        |                     |            |         |            |         |
| Kidney                          | 70 (56.4)               | 28 (60.5)           | .910      | .       |            |         |
| Liver                           | 28 (22.5)               | 7 (18.4)            | .         | .       |            |         |
| Kidney and liver                | 1 (0.8)                 | 0                   | .         | .       |            |         |
| Kidney and pancreas             | 1 (0.8)                 | 0                   | .         | .       |            |         |
| Heart                           | 14 (11.29)              | 2 (5.2)             |           | .       |            |         |
| Heart and kidney                | 3 (2.4)                 | 0                   | .         | .       |            |         |
| Lung                            | 7 (5.6)                 | 1                   |           | .       |            |         |
| Age                             | 54 [45-64]              | 63 [57-71]          | <.001     | .001    | 1.07 (1.03-1.11) | .001    |
| Sex                             |                        |                     |            |         |            |         |
| M                               | 88 (70.9)               | 23 (60.5)           | 0.6 (0.2-1.3) | .237    |            |         |
| F                               | 36 (29)                 | 15 (39)             |           | .       |            |         |
| Comorbidities (any)             | 92 (82.8)               | 34 (94)             | 3.3 (0.7-15) | .160    |            |         |
| Hypertension                    | 66 (59)                 | 27 (75)             | 2 (0.8-4.7) | .113    |            |         |
| Diabetes mellitus               | 38 (34.2)               | 11 (30.5)           | 0.8 (0.3-1.9) | .839    |            |         |
| Months after transplant         | 73 [20-175]             | 102 [48-186]        | .118      | .       |            |         |
| Immune suppressing agents       |                        |                     |            |         |            |         |
| Tacrolimus                      | 93 (75)                 | 24 (64.8)           | 0.6 (0.28-1.3) | .293    |            |         |
| Tacrolimus dose mg              | 4 [2-7]                 | 8.5 [5-]            | .227      | .       |            |         |
| Mycophenolate                   | 80 (64.5)               | 26 (68.4)           | 1.3 (0.6-3) | .811    |            |         |
| Cyclosporin A                   | 14 (11.2)               | 7 (18.4)            | 1.7 (0.6-4.7) | .274    |            |         |
| Steroids                        | 81 (65.3)               | 26 (68.4)           | 1.15 (0.5-2.5) | .845    |            |         |
| mTor inhibitor                  | 13 (10.4)               | 5 (13.1)            | 1.2 (0.4-3.8) | .768    |            |         |
| Azathioprine                    | 8 (6.4)                 | 3 (7.8)             | 1.2 (0.3-4.9) | .721    |            |         |

Hematochemical data at baseline

| Parameter                        | Outcome                               | Univariate analysis | Multivariate analysis |
|---------------------------------|---------------------------------------|---------------------|-----------------------|
|                                 | Survived (N = 124) | Deceased (N = 38)  | OR 95% CI | P value | OR 95% CI | P value |
| White blood cells, cells/µL     | 5040 [3900-6300]   | 7240 [4300-9100]   | .035          | .       |            |         |
| Lymphocyte, cells/µL            | 651 [423-1102]     | 715 [442-1175]     | .618          | .       |            |         |
| Lactate dehydrogenase, U/L      | 277 [246-372]      | 444 [317-737]      | .004          | .       |            |         |
| Procalcitonin, ng/mL            | 0.15 [0.07-0.28]   | 0.22 [0.12-0.3]    | .296          | .       |            |         |
| C-reactive protein mg/L         | 47 [19-88]         | 65 [34-172]        | .069          | .       |            |         |
| Creatinine, mg/dl               | 1.7 [1.13-2.2]     | 2.1 [1.4-3.4]      | .157          | .       |            |         |

(Continues)
Table 2 (Continued)

| Parameter                              | Outcome | Univariate analysis | Multivariate analysis |
|----------------------------------------|---------|---------------------|-----------------------|
| Interleukin 6, pg/mL                   | 24 [6.7-34] | 141 [65-465] | 0.002 | 3.3 [1.2-8.5] | 0.013 |
| D-dimer, ng/mL                         | 961 [638-1470] | 950 [540-2239] | 1.000 | |
| Ferritine, ng/mL                       | 336 [157-875] | 994 [817-2724] | 0.006 | 0.3 [0.1-0.7] | 0.013 |
| Tacrolimus blood levels, ng/mL         | 7.7 [5.8-12.9] | 8.5 [8.5-8.5] | 0.693 | 0.3 [0.1-0.7] | 0.013 |
| Symptoms at diagnosis                  |         |                     |                       |
| Fever                                  | 95 (76.6) | 34 (89.4) | 2.5 (0.8-7.9) | 0.108 |
| Respiratory symptoms                   | 90 (75) | 32 (90.9) | 10.6 (1.3-81.4) | 0.003 |
| Gastro-intestinal symptoms             | 41 (34.1) | 10 (26.3) | 0.8 (0.3-1.9) | 0.835 |
| Interval from symptom onset to diagnosis | 5 days [3-8] | 4 [2-7] | 0.7 (0.7-0.8) | 0.777 |
| Abnormal lung CT scan at diagnosis     | 91 (82.7) | 26 (68) | 0.7 (0.7-0.8) | 0.024 |
| Medical treatment for COVID-19         |         |                     |                       |
| Antivirals                             |         |                     |                       |
| Lopinavir regimen                      | 19 (15.3) | 7 (18.9) | 4.6 (2.0-10.4) | <.001 |
| Darunavir regimen                      | 1 (0.8) | 3 (8.1) | 10.8 (1.0-107) | 0.038 |
| Hydroxychloroquine                     | 75 (60.9) | 27 (72.9) | 1.7 (0.7-3.8) | 0.242 |
| Interferon                             | 7 (5.6) | 5 (13.5) | 2.5 (0.7-8.7) | 0.150 |
| Remdesivir                             | 3 (2.4) | 1 (2.7) | 1.1 (0.1-11) | 1.000 |
| Steroids                               | 88 (70.9) | 28 (77.7) | 1.4 (0.5-3.4) | 0.527 |
| Intravenous immunoglobulin             | 18 (12.2) | 4 (10.8) | 0.7 (0.2-2.2) | 0.786 |
| Anti-Interleukin 6                     | 19 (15.4) | 11 (29.7) | 2.3 (0.9-5.4) | 0.058 |
| Tacrolimus maintained                   | 75 (60.9) | 10 (27) | 0.2 (0.1-0.5) | <.001 |
| Mycophenolate maintained               | 28 (22.7) | 3 (8.1) | 0.2 (0.08-1) | 0.058 |
| Respiratory support                    |         |                     |                       |
| Non-invasive ventilation               | 62 (53.9) | 23 (74.1) | 2.4 (1.5-9) | 0.064 |
| Invasive mechanical ventilation        | 11 (9.3) | 24 (66.6) | 19.4 (7.6-49.3) | <.001 |
| COVID-19 disease                       |         |                     |                       |
| Asymptomatic                           | 2 (2.1) | 0 | <.001 |
| Mild                                   | 13 (12) | 0 |  |
| Moderate                               | 30 (27.7) | 0 |  |
| Severe                                 | 52 (48.1) | 11 (31.4) |  |
| Critical                               | 11 (10.1) | 24 (68) |  |
data suggest that mortality was actually lower in SOTR who did not undergo changes to immune suppressive therapy. Up to 60% of patients who did not have their immune suppressive regimen changed were symptomatic and showed pulmonary imaging positive for COVID-19 pneumonia, suggesting that at baseline the disease could have progressed toward more severe stages also in these patients.

In a recent report, maintaining the immune suppressive therapy was recommended only for asymptomatic or milder cases, without high risk conditions (including comorbidities), and was not recommended in those receiving dual therapy plus steroids. However, we observed that SOTR who continued their previous therapy developed as the worst presentation mostly moderate (33.3%) and severe (35.8) COVID-19, despite 80% of them had comorbidities and 33.3% were on dual therapy plus steroid. In contrast, those who modified immune suppressive regimen appeared to mostly progress toward severe (45%) and critical (35%) disease. There was an association between respiratory support requirement and reduction or discontinuation of immune suppression. In particular, patients in need for ventilatory support more frequently changed immunosuppression (Table 3). However, we are unable to define whether the oxygen requirement increased because of a change in immune suppression or rather the change in immune suppression was driven by a worsening respiratory condition. Mortality in the maintaining treatment group was 2.2% compared to 23.8% of those changing regimen. Thus, these data suggest that not only asymptomatic and mild cases could continue their previous immune suppressive regimen, but moderate and, possibly, severe cases as well.

Regarding critical patients, our data do not provide any answer. Interestingly, no patient who continued their immune suppressive treatment progressed to critical COVID-19. On the other hand, all patients who developed critical disease had their immune suppressive regimen changed/withdrawn. Thus, we believe that consideration should be given to the possibility that changes in immunosuppressive therapy may not correlate to a better outcome in SOTR with COVID-19. This hypothesis appears plausible in light of the studies suggesting that hyperinflammation and cytokine storm are related to mortality in COVID-19.

A similar reasoning could apply to the use of tacrolimus, since the group that did not receive treatment with tacrolimus had higher baseline inflammatory markers and was significantly more symptomatic, showing more often a positive pulmonary imaging. However, in the group continuing tacrolimus, more than 70% were symptomatic and with positive lung imaging. More patients not treated with tacrolimus had a critical stage as their worst COVID-19 presentation (40% vs 14.7% in the tacrolimus group), although the two groups had a similar rate of severe COVID-19 (42.3% vs 46.5%). Interestingly, overall mortality was 27.3% vs only 9.9% among those maintaining tacrolimus.

Tacrolimus showed in vitro activity against SARS-CoV-1 and was therefore suggested as a potential COVID-19 treatment. Interestingly, mortality was already shown to be as low as 8% in a cohort of patients who continued their immune suppressive treatment with tacrolimus (96%), although at a reduced dose.
| Parameter | Withdrawal of immune suppressors | Univariate analysis |
|-----------|---------------------------------|---------------------|
|           | None (N = 45)                  | Partially or complete (N = 152) | OR 95% CI | P value |
| Type of transplant | | | | | |
| Kidney | 13 (28.8) | 111 (73) | | <.001 |
| Liver | 26 (57.7) | 13 (8.5) | | |
| Kidney and liver | 1 (2.2) | 0 | | |
| Kidney and pancreas | 0 | 1 (0.6) | | |
| Heart | 2 (4.4) | 17 (11.1) | | |
| Heart and kidney | 0 | 1 (0.6) | | |
| Lung | 3 (6.6) | 6 (3.9) | | |
| Face | 0 | 1 (0.6) | | |
| Age | 54 [44-65] | 58 [50-67] | | .206 |
| Sex | | | | | |
| M | 30 (66.6) | 105 (69) | 1.1 (0.5-2.2) | .855 |
| F | 15 (33.3) | 47 (30.9) | | |
| Comorbidities (any) | | | | | |
| Hypertension | 34 (80.9) | 122 (80.2%) | 2 (0.7-5.2) | .177 |
| Diabetes mellitus | 18 (42.8) | 100 (65.7) | 3.6 (1.7-7.3) | .001 |
| Months after transplant | 76 [13-202] | 78 [30-165] | | .870 |
| Immune suppressing agents | | | | | |
| Tacrolimus | 29 (64.4) | 116 (76.3) | 1.8 (0.8-3.7) | .121 |
| Tacrolimus dose mg | 2 [1-6] | 4 [2-7] | | .138 |
| Mycophenolate | 19 (42.2) | 111 (73) | 3.7 (1.8-7.5) | <.001 |
| Cyclosporin A | 6 (13.3) | 20 (13) | 0.9 (0.3-2.6) | 1.000 |
| Steroids | 23 (51.1) | 115 (75) | 2.9 (1.4-5.9) | .003 |
| mTor inhibitor | 4 (8.8) | 16 (10.5) | 1.2 (0.3-3.8) | 1.000 |
| Azathioprine | 5 (11.1) | 8 (5.2) | 0.4 (0.1-1.4) | .178 |
| Hematological data at baseline | | | | | |
| White blood cells, cells/µL | 4600 [3180-6217] | 5600 [4500-8310] | | .011 |
| Lymphocyte, cells/µL | 660 [350-1120] | 640 [420-1105] | | .946 |
| Lactate dehydrogenase, U/L | 224 [151-292] | 353 [272-545] | | .028 |
| Procalcitonin, ng/mL | 0.17 [0.07-0.3] | – | | |
| C-reactive protein, mg/L | 47 [10-98] | 51 [31-126] | | .366 |
| Creatinine, mg/dL | 1 [0.9-1.4] | 1.9 [1.4-2.6] | | .008 |
| Interleukin, 6 pg/mL | 26 [26-26] | 62 [24-141] | | .435 |
| D-dimer, ng/mL | 1020 [1020-1020] | 1109 [609-2163] | | .911 |
| Ferritin, ng/mL | 610 [266-1160] | – | | .006 |
| Tacrolimus blood levels, ng/mL | 6.6 [3.2-7.2] | 8.6 [7.6-21.7] | | .004 |
| Symptoms at diagnosis | | | | | |
| Fever | 26 (59) | 130 (85.5) | 4.3 (2-9.1) | <.001 |
| Respiratory symptoms | 32 (72.7) | 107 (81) | 1.6 (0.7-3.5) | .286 |
| Gastro-intestinal symptoms | 9 (41) | 50 (37.8) | 0.4 (0.1-0.9) | .042 |
| Interval from symptom onset to diagnosis | 4 days [1-7] | 4 [2-7] | | .586 |
| Abnormal lung CT scan at diagnosis | 24 (61.5) | 110 (93.2) | 8.5 (3.2-22.5) | <.001 |

(Continues)
### TABLE 3 (Continued)

| Parameter                                      | Withdrawal of immune suppressors | Univariate analysis |
|------------------------------------------------|----------------------------------|---------------------|
|                                                 | None (N = 45) | Partially or complete (N = 152) | OR 95% CI | P value |
| Medical treatment for COVID-19                 |                  |                                |           |         |
| Antivirals                                     |                  |                                |           |         |
| Lopinavir regimen                              | 3 (6.6)          | 44 (29.1)                      | 5.7 (1.6-19.5) | .001 |
| Darunavir regimen                              | 0                | 9 (5.9)                        | 1.3 (1.2-1.4) | .122 |
| Hydroxychloroquine                             | 16 (35.5)        | 109 (72.1)                     | 4.7 (2.3-9.5) | <.001 |
| Interferon                                     | 2 (4.4)          | 11 (7.2)                       | 1.6 (0.3-7.8) | .736 |
| Remdesivir                                     | 1 (2.2)          | 5 (3.3)                        | 1.5 (0.1-13.2) | 1.000 |
| Steroids                                       | 21 (46.6)        | 129 (85.4)                     | 6.7 (3.1-14) | <.001 |
| Intravenous immunoglobulin                     | 3 (6.6)          | 22 (14.6)                      | 2.4 (0.6-8.4) | .207 |
| Anti-Interleukin 6                             | 3 (6.6)          | 34 (22.5)                      | 4 (1.1-13.9) | .017 |
| Tacrolimus continued                           | 28 (63.6)        | 70 (46)                        | 0.4 (0.2-0.9) | .059 |
| Respiratory support                            |                  |                                |           |         |
| Non-invasive ventilation                       | 14 (31.8)        | 89 (66.9)                      | 4 (2.8-9) | <.001 |
| Invasive mechanical ventilation                | 0                | 47 (32.4)                      | 1.4 (1.2-1.6) | <.001 |
| COVID-19 disease                               |                  |                                |           |         |
| Asymptomatic                                   | 2 (5.2)          | 0                              | <.001 |
| Mild                                           | 10 (25.6)        | 5 (3.7)                        |           |         |
| Moderate                                       | 13 (33.3)        | 20 (15.1)                      |           |         |
| Severe                                         | 14 (35.8)        | 60 (45.4)                      |           |         |
| Critical                                       | 0                | 47 (35.6)                      |           |         |
| Outcomes                                       |                  |                                |           |         |
| Survived/cured                                 | 39 (86.6)        | 83 (54.9)                      | <.001 |
| Deceased                                       | 1 (2.2)          | 36 (23.8)                      |           |         |
| Ongoing hospitalization                        | 5 (11.1)         | 33 (21.8)                      |           |         |

Note: Data are median (IQR) or number (%). 
P values denoting statistical significance of the differences are in bold.

### TABLE 4 Characteristics of patients according to ongoing treatment with tacrolimus

| Parameter                  | Ongoing tacrolimus | Univariate analysis |
|----------------------------|--------------------|---------------------|
|                            | No (N = 98) | Yes (N = 101) | OR 95% CI | P value |
| Type of transplant         |                |                |           |         |
| Kidney                     | 72 (73.4)      | 51 (50.4)      |           | .010   |
| Liver                      | 17 (17.4)      | 24 (23.7)      |           |         |
| Kidney and liver           | 0              | 1 (0.9)        |           |         |
| Kidney and pancreas        | 1 (1)          | 0              |           |         |
| Heart                      | 7 (7.1)        | 12 (11.8)      |           |         |
| Heart and kidney           | 0              | 3 (2.9)        |           |         |
| Lung                       | 1 (1)          | 9 (8.9)        |           |         |
| Face                       | 0              | 1 (0.9)        |           |         |
| Age                        | 58 [50-65]     | 56 [48-67]     |           | .594   |
| Sex                        |                |                |           |         |
| M                          | 71 (66.6)      | 67 (69)        | 1.3 (0.7-2.4) | .361 |
| F                          | 27 (33.3)      | 34 (30.9)      |           |         |

(Continues)
| Parameter                      | Ongoing tacrolimus | Univariate analysis | P value |
|-------------------------------|--------------------|---------------------|---------|
|                               | No (N = 98)        | Yes (N = 101)       | OR 95% CI |         |
| Comorbidities (any)           | 79 (88.7)          | 79 (86.8)           | 0.8 (0.3-2) | .821 |
| Hypertension                  | 63 (70)            | 57 (62.6)           | 0.7 (0.3-1.3) | .346 |
| Diabetes mellitus             | 20 (22.2)          | 40 (43.9)           | 2.7 (1.4-5.2) | .003 |
| Months after transplant       | 120 [54-193]       | 48 [13-97]          | <.001    |
| Hematochemical data at baseline |                   |                     |          |
| White blood cells, cells/µL  | 5900 [4360-7947]   | 5040 [3547-7737]    | .126     |
| Lymphocyte, cells/µL         | 643 [420-1100]     | 680 [397-1132]      | .738     |
| Lactate dehydrogenase, U/L   | 224 [151-292]      | 353 [272-545]       | .015     |
| Procalcitin, ng/mL           | 0.18 [0.11-0.2]    | 0.16 [0.06-0.4]     | .839     |
| C-reactive protein, mg/L     | 67 [35-135]        | 40 [16-97]          | .025     |
| Creatinine, mg/dl            | 2.2 [1.7-2.8]      | 1.5 [1.1-1.9]       | .022     |
| Interleukin, 6 pg/mL         | 91 [21-229]        | 31 [20-63]          | .192     |
| D-dimer, ng/mL               | 707 [448-1290]     | 1194 [926-2692]     | .052     |
| Ferritine, ng/mL             | 830 [523-1754]     | 429 [157-1115]      | .063     |
| Symptoms at diagnosis        |                   |                     |          |
| Fever                         | 85 (86.7)          | 73 (72.2)           | 0.3 (0.1-0.8) | .014 |
| Respiratory symptoms         | 64 (82)            | 78 (77.2)           | 0.7 (0.3-1.5) | .462 |
| Gastro-intestinal symptoms   | 32 (41)            | 28 (27)             | 0.5 (0.2-1) | .079 |
| Interval from symptom onset to diagnosis | 4 days [1-7]  | 4 [2-7] | .586 |
| Abnormal lung CT scan at diagnosis | 64 (94.1) | 73 (80) | 0.2 (0.08-0.7) | .019 |
| Medical treatment for COVID-19 |                   |                     |          |
| Antivirals                    |                   |                     |          |
| Lopinavir regimen             | 36 (37)            | 13 (12.8)           | 0.2 (0.1-0.5) | <.001 |
| Darunavir regimen             | 9 (9)              | 0                   | 0.4 (0.4-0.5) | .001 |
| Hydroxychloroquine            | 66 (68)            | 62 (61.3)           | 0.7 (0.4-1.3) | .373 |
| Interferon                    | 8 (8.2)            | 5 (4.9)             | 0.5 (0.1-1.8) | .736 |
| Remdesivir                    | 1 (1)              | 5 (4.9)             | 5 (0.5-43) | .212 |
| Steroids                      | 81 (83.5)          | 69 (68.3)           | 0.4 (0.2-0.8) | .014 |
| Intravenous immunoglobulin    | 16 (16.4)          | 9 (8.9)             | 0.5 (0.2-1.1) | .136 |
| Anti-Interleukin 6            | 26 (26.8)          | 11 (10.8)           | 0.3 (0.1-1.6) | .006 |
| Non-invasive ventilation      | 57 (64.7)          | 49 (53)             | 0.6 (0.3-1.1) | .171 |
| Invasive ventilation          | 34 (36)            | 13 (13.4)           | 0.2 (0.1-0.5) | <.001 |
| COVID-19 disease              |                   |                     |          |
| Asymptomatic                  | 0                  | 2 (2.3)             | <.001    |
| Mild                          | 2 (2.3)            | 12 (13.6)           |          |
| Moderate                      | 13 (15.2)          | 20 (22.7)           |          |
| Severe                        | 36 (42.3)          | 41 (46.5)           |          |
| Critical                      | 34 (40)            | 13 (14.7)           |          |
| Outcome                       |                   |                     |          |
| Survived/Cured                | 48 (49.4)          | 75 (74.2)           | .001     |
| Deceased                      | 27 (27.3)          | 10 (9.9)            |          |
| Ongoing hospitalization       | 22 (22.6)          | 16 (14.8)           |          |

Note: Data are median (IQR) or number (%). P values denoting statistical significance of the differences are in bold.
| Parameter | Ongoing mycophenolate | Univariate analysis |  
|-----------|----------------------|---------------------|  
| Type of transplant |  |  |  
| Kidney | 107 (64.8) | 17 (50) | [.121]  
| Liver | 29 (17.5) | 12 (35.2) |  
| Kidney and liver | 1 (0.6) | 0 |  
| Kidney and pancreas | 0 | 1 (2.9) |  
| Heart | 16 (9.6) | 3 (8.8) |  
| Heart and kidney | 3 (1.8) | 0 |  
| Lung | 8 (4) | 1 (8.9) |  
| Face | 1 | 0 |  
| Age | 57 [49-67] | 57.5 [45-64] | .621  
| Sex |  |  |  
| M | 114 (69.1) | 23 (67.6) | 1 (0.4-2.3) | .842  
| F | 51 (30.9) | 11 (32.3) |  
| Comorbidities (any) | 128 (87) | 30 (90.9) | 1.4 (0.4-5.3) | .770  
| Hypertension | 100 (67.5) | 20 (60.6) | 0.7 (0.3-1.6) | .542  
| Diabetes mellitus | 48 (32.4) | 12 (36.3) | 1.1 (0.5-2.6) | .686  
| Months after transplant | 83 [30-183] | 76 [12-158] | .202  
| Hematochemical data at baseline |  |  |  
| White blood cells, cells/µL | 5300 [3940-7800] | 5900 [4300-7100] | .579  
| Lymphocyte, cells/µL | 641 [420-1085] | 700 [400-1500] | .861  
| Lactate dehydrogenase, U/L | 347 [272-531] | 172 [154-] | .020  
| Procalcitonin, ng/mL | 0.18 [0.1-0.31] | 0.07 [0.07-0.07] | .329  
| C-reactive protein, mg/L | 51.4 [31-119] | 47 [18-97] | .525  
| Creatinine, mg/dL | 1.9 [1.4-2.4] | 0.9 [0.8-1.7] | .003  
| Interleukin, 6 pg/mL | 62 [24-141] | 26 [26-26] | .435  
| D-dimer, ng/mL | 1022 [565-2410] | 1133 [1020-] | .738  
| Ferritine, ng/mL | 593 [251-1164] | 915 [915-915] | .603  
| Symptoms at diagnosis |  |  |  
| Fever | 135 (81.8) | 23 (67.6) | 0.4 (0.2-1.05) | .100  
| Respiratory symptoms | 112 (77.2) | 29 (85.2) | 2.1 (0.7-6.5) | .236  
| Gastro-intestinal symptoms | 51 (35.1) | 9 (27.2) | 0.6 (0.2-1.5) | .423  
| Interval from symptom onset to diagnosis | 4 days [1-6] | 7 [3-9] | .021  
| Abnormal lung CT scan at diagnosis | 112 (86.8) | 24 (80) | 0.6 (0.2-1.7) | .571  
| Medical treatment for COVID-19 |  |  |  
| Antivirals |  |  |  
| Lopinavir regimen | 39 (23.7) | 10 (29.4) | 1.3 (0.5-3) | .515  
| Darunavir regimen | 9 (5.4) | 0 | 0.8 (0.7-0.8) | .362  
| Hydroxychloroquine | 113 (68.9) | 14 (41.1) | 0.3 (0.1-0.6) | .003  
| Interferon | 12 (7.3) | 1 (2.9) | 0.3 (0.04-3) | .702  
| Remdesivir | 6 (3.6) | 0 | 0.8 (0.7-0.8) | .592  
| Steroids | 130 (78.7) | 20 (58.8) | 0.3 (0.1-0.8) | .016  
| Intravenous immunoglobulin | 22 (13.3) | 3 (8.8) | 0.6 (0.1-2.2) | .580  
| Anti-Interleukin 6 | 35 (21.3) | 2 (5.8) | 0.2 (0.05-1) | .050  

(Continues)
The protective role of immune suppression from CNI in transplanted patients or steroids in general population is being assessed. For instance, one study described protective effects of cyclosporine (CNI) treatment in transplanted patients. An ongoing clinical trial is assessing treatment with tacrolimus and methylprednisolone for COVID-19 patients. Discontinuation of immune suppressors did not provide any benefit to a cohort of liver transplant recipients. A beneficial effect of steroids in lowering COVID-19 associated mortality has been suggested. From our observation, steroid treatment was not related to survival. However, it was associated with immune suppressive treatment withdrawal and negatively correlated to tacrolimus and mycophenolate continuation. Mycophenolate is the first immune suppressive drug to be withdrawn in kidney transplant patients <60 years old with pneumonia without hypoxemia and in patients >60 years old even without pneumonia. Since its effect in inhibition of B lymphocytes, the consideration is that mycophenolate could have a negative effect regarding COVID-19 in SOTR. However, in a study by Cheng et al., mycophenolate was shown to have antiviral activity against MERS-CoV by inhibiting Papain-like protease, a protein found to regulate viral spread for SARS-CoV-2 too. Our data suggest that mycophenolate also exerted a protective effect in terms of COVID-19 mortality, although to a lower extent than tacrolimus. Treatment with lopinavir was not associated with survival, in line with previous studies. In SOTR, many patients withdrew tacrolimus to start lopinavir/ritonavir because of their pharmacokinetic interaction, making it particularly difficult to give both drugs concurrently.

Our study has several limitations, mostly inherent to the type of analyzed data. For many patients follow up was not complete and many were still hospitalized at the time of reporting. However, we did not include this subset of patients in the analysis of outcome. We could not provide any data on mid-term follow up or other transplant related outcomes, including de novo donor specific antibody formation or subsequent graft loss. The beneficial effect of continuing immune suppression could have been the result of confounders that, based on available data, could not be accounted for in our analysis. Also, we acknowledge that the therapeutic approach used in included patients may be outdated because of fast changing knowledge on this new disease. Finally, we could not provide definitive data on the timing of immune modification in relation to the time course of infection.

In conclusion, our study suggests that ongoing immune suppressive therapy may be safe in moderate and severe COVID-19 SOTR, and that treatment with tacrolimus and, possibly, mycophenolate, may be associated with survival. Further studies are needed to corroborate our results and to provide further answers to the question of how to optimally manage immune suppression in SOTR with COVID-19. Because of the quality of the available evidence, we could not provide more definitive guidance on how to manage SOTR with COVID-19.

DISCLOSURE
The authors declare no conflicts of interest.

AUTHORS CONTRIBUTION
AK, RZ, EDM worked on concept of the study; SP, AS worked on data collection and data interpretation; FB, FP, MG worked on statistical analysis; AK, RZ and EDM drafted the manuscript; CM and all authors critically revised the manuscript.

DATA AVAILABILITY STATEMENT
The dataset generated for this study are available on request to the corresponding author.
REFERENCES

1. Zhou P, Yang X-L, Wang X-G, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579:270-273.
2. Chen Y, Liu Q, Guo D. Emerging coronaviruses: genome structure, replication, and pathogenesis. J Med Virol. 2020;92:418-423.
3. Siddiqi HK, Mehta MR. COVID-19 illness in native and immunosuppressed states: a clinical-therapeutic staging proposal. J Heart Lung Transplant. 2020;39(5):405-407. https://doi.org/10.1016/j.healun.2020.03.012
4. Jiang F, Deng L, Zhang L, et al. Review of the clinical characteristics of coronavirus disease 2019 (COVID-19). J Gen Intern Med. 2020;35(5):1545-1549. https://doi.org/10.1007/s11606-020-05762-w
5. Adhikari SP, Meng S, Wu Y-J, et al. Epidemiology, causes, clinical manifestation and diagnosis, prevention and control of coronavirus disease (COVID-19) during the early outbreak period: a scoping review. Infect Dis Poverty. 2020;9(1):29.
6. Lippi G, Plebani M. Laboratory abnormalities in patients with COVID-2019 infection. Clin Chem Lab Med. 2020;58(7):1131-1134. https://doi.org/10.1515/cclm-2020-0198
7. Wang H, Luo SH, Shen Y, et al. Multiple enzyme release, inflammation storm and hypercoagulability are prominent indicators for disease progression in COVID-19: a multi-centered, correlation study with CT imaging score. SSRN. 2020. https://doi.org/10.2139/ssrn.3544837
8. Aklain E, Azzi Y, Bartash R, et al. COVID-19 and kidney transplantation. N Engl J Med. 2020;382(25):2475-2477. https://doi.org/10.1056/NEJMc2011117
9. Hoek RAS, Manintveld OC, Betjes MGH, et al. COVID-19 in solid organ transplant recipients: a single-center experience. Transpl Int. 2020;33(9):1076-1082. https://doi.org/10.1111/tci.13662
10. Alberici F, Delbarba E, Manenti C, et al. A single center observational study of the clinical characteristics and short-term outcome of 20 kidney transplant patients admitted for SARS-CoV2 pneumonia. Kidney Int. 2020;97(6):1083-1088. https://doi.org/10.1016/j.kint.2020.04.002
11. World Health Organisation. Clinical management of COVID-19. Available at: https://www.who.int/publications/i/item/clinical-management-of-covid-19
12. Banerjee D, Popoola J, Shah S, Ster IC, Quan V, Phanish M. COVID-19 infection in kidney transplant recipients. Kidney Int. 2020;97(6):1076-1082. https://doi.org/10.1016/j.kint.2020.03.018
13. Guillon E, Pinejo GR, Revueltl L, et al. Case report of COVID-19 in a kidney transplant recipient: does immunosuppression alter the clinical presentation? Am J Transplant. 2020;20(7):1875-1878. https://doi.org/10.1111/ajt.15874
14. Zhu L, Xu X, Ma KE, et al. Successful recovery of COVID-19 pneumonia in a renal transplant recipient with long-term immunosuppression. Am J Transplant. 2020;20(7):1859-1863.
15. Huang J, Lin H, Wu Y, et al. COVID-19 in post-transplantation patients- report of two cases. Am J Transplant. 2020;20(7):1879-1881. https://doi.org/10.1111/ajt.15896
16. Liu B, Wang Y, Zhao Y, Shi H, Zeng F, Chen Z. Successful treatment of severe COVID-19 pneumonia in a liver transplant recipient. Am J Transplant. 2020;20(7):1891-1895. https://doi.org/10.1111/ajt.15901
17. Chen S, Yin Q, Shi H, et al. A familial cluster, including a kidney transplant recipient, of Coronavirus Disease 2019 (COVID-19) in Wuhan, China. Am J Transplant. 2020;20(7):1869-1874. https://doi.org/10.1111/ajt.15903
18. Seminari E, Colaneri M, Sambo M, et al. SARS CoV2 infection in a renal transplanted patient. A case report. Am J Transplant. 2020;20(7):1882-1884. https://doi.org/10.1111/ajt.15902
19. Gandolfini I, Delante M, Fiacchadori E, et al. COVID-19 in kidney transplant recipients. Am J Transplant. 2020;20(7):1941-1943. https://doi.org/10.1111/ajt.15891
20. Li Q, Cheng Q, Zhao Z, et al. Novel coronavirus infection and acute kidney injury in two renal transplant recipients: case report. Preprints. 2020;2020030190.
21. Qin J, Wang H, Qin X, et al. Perioperative presentation of COVID-19 disease in a liver transplant recipient. Hepatology. 2020;72(4):1491-1493. https://doi.org/10.1002/hep.31257
22. Li F, Cai J, Dong N. First cases of COVID-19 in heart transplantation from China. J Heart Lung Transplant. 2020;39(5):496-497. https://doi.org/10.1016/j.healun.2020.03.006
23. Bussalino E, De Maria A, Russo R, Paolotti E. Immunosuppressive therapy maintenance in a kidney transplant recipient SARS-CoV-2 pneumonia: a case report. Am J Transplant. 2020;20(7):1922-1924. https://doi.org/10.1111/ajt.15920
24. Qing L, Liu L, Li W, et al. Novel coronavirus (SARS-CoV-2) infection in a renal transplant recipient: case report. Am J Transplant. 2020;20(7):1864-1866. https://doi.org/10.1111/ajt.15897
25. Marx D, Moulin B, Fafi-Kremer S, et al. First case of COVID-19 in a kidney transplant recipient treated with belatacept. Am J Transplant. 2020;20(7):1944-1946. https://doi.org/10.1111/ajt.15919
26. Huang J-F, Zheng KJ, George J, et al. Fatal outcome in a liver transplant recipient with COVID-19. Am J Transplant. 2020;20(7):1907-1910. https://doi.org/10.1111/ajt.15909
27. Fernández-Ruiz M, Andrés A, Loinaz C, et al. COVID-19 in solid organ transplant recipients: a single-center case series from Spain. Am J Transplant. 2020;20(7):1849-1858. https://doi.org/10.1111/ajt.15929
28. Lima B, Gibson GT, Vullangi S, et al. COVID-19 in recent heart transplant recipients: clinicopathologic features and early outcomes. Transpl Infect Dis. 2020;22(5):e13382. https://doi.org/10.1111/tid.13382
29. Vaidya G, Czer LSC, Kobashigawa J, et al. Successful treatment of severe COVID-19 pneumonia with clazakizumab in a heart transplant recipient: a case report. Transplant Proc. 2020;52(9):2711-2714. https://doi.org/10.1016/j.transproceed.2020.06.003
30. Jang K, Khatri A, Majure DT. COVID-19 leading to acute encephalopathy in a patient with heart transplant. J Heart Lung Transplant. 2020;39(8):853-855. https://doi.org/10.1016/j.healun.2020.05.016
31. Holzhauser L, Lourenco L, Sarswat N, Kim G, Chung B, Nguyen AB. Early experience of COVID-19 in 2 heart transplant recipients: case reports and review of treatment options. Am J Transplant. 2020;20(10):2916-2922. https://doi.org/10.1111/ajt.15982
32. Mattioli M, Fustini E, Gennarini S. Heart transplant recipient patient with COVID-19 treated with tocilizumab. Transpl Infect Dis. 2020;22(6):e13380. https://doi.org/10.1111/tid.13380
33. Hsu JJ, Gaynor P, Kamath M, et al. COVID-19 in a high-risk dual heart and kidney transplant recipient. Am J Transplant. 2020;20(7):1911-1915. https://doi.org/10.1111/ajt.15936
34. Aigner C, Dittmer U, Kamler M, Collaud S, Taube C. COVID-19 in a lung transplant recipient. J Heart Lung Transplant. 2020;39(6):610-611. https://doi.org/10.1016/j.healun.2020.04.004
35. Meziryeh S, Zwart TC, Etten RW, et al. Severe COVID-19 in a renal transplant recipient: a focus on pharmacokinetics. Am J Transplant. 2020;20(7):1896-1901. https://doi.org/10.1111/ajt.15943
36. Nair V, Jandovitz N, Hirsch JS, et al. COVID-19 in kidney transplant recipients. Am J Transplant. 2020;20(7):1819-1825. https://doi.org/10.1111/ajt.15967
37. Fung M, Chiu CY, DeVoe C, et al. Clinical outcomes and serologic response in solid organ transplant recipients with COVID-19: a case
series from the United States. Am J Transplant. 2020;20(11):3225-3233. https://doi.org/10.1111/ajt.16079

38. Verma A, Khorsandie SE, Dolcet A, et al. Low prevalence and disease severity of COVID-19 in post-liver transplant recipients: a single centre experience. Liver Int. 2020;40(8):1972-1976. https://doi.org/10.1111/liv.14555

39. Jiang J, Mao Y, Zhao Y, et al. Convalescent plasma therapy: helpful treatment of COVID-19 in a kidney transplant recipient presenting with severe clinical manifestation and complex complications. Clin Transplant. 2020;34:e14025. https://doi.org/10.1111/ctr.14025

40. Chen D, Yang BO, Zhang Y, et al. Withdrawing mycophenolate mofetil in a kidney transplant recipient suffering from severe SARS-CoV-2 pneumonia. Transpl Infect Dis. 2019;22(6):e13348. https://doi.org/10.1111/tid.13348

41. Xu JJ, Samaha D, Mondhe S, et al. COVID-19 pneumonia in a liver transplant recipient on hemodialysis and response to tocilizumab. Transpl Infect Dis. 2020;22(4):e13326. https://doi.org/10.1111/tid.13326

42. Kocak B, Arpalı E, Akyollu B, et al. A case report of oligosymptomatic atypical kidney transplant patients with COVID-19: do they pose a risk to other recipients. Transplant Proc. 2020;52(9):2663-2666. https://doi.org/10.1016/j.transproceed.2020.05.028

43. Modii AR, Koval CE, Taege AJ, et al. In an orthotopic liver transplant recipient living with human immunodeficiency virus. Transpl Infect Dis. 2019;22(2):e13351. https://doi.org/10.1111/tid.13351

44. Mathies D, Rauschning D, Wagner U, et al. A case of SARS-CoV-2 pneumonia with successful antiviral therapy in a 77-year-old man with a heart transplant. Am J Transplant. 2020;20(7):1925-1929. https://doi.org/10.1111/ajt.15932

45. Allam SR, Daa O, Madhira MM, et al. Interleukin-6 receptor antagonist therapy to treat SARS-CoV-2 driven inflammatory syndrome in a kidney transplant recipient. Transpl Infect Dis. 2020;22(4):e13326. https://doi.org/10.1111/tid.13326

46. Loinaz C, Marcaccuzo A, Fernandez-Miquel M, et al. Varied clinical presentation and outcome of SARS-CoV-2 infection in liver transplant recipients: initial experience at a single center in Madrid, Spain. Transpl Infect Dis. 2020;22(2):e13372. https://doi.org/10.1111/tid.13372

47. Vellugu A, Tuglular S. Care of asymptomatic SARS-CoV-2 positive kidney transplant recipients. Transpl Int. 2020;33(10):1331-1332. https://doi.org/10.1111/tri.13691

48. Bussalino E, De Maria A, Russo R, Paolotti E. Immunosuppressive therapy maintenance in a kidney transplant recipient with SARS-CoV-2 pneumonia: a case report. Am J Transplant. 2020;20(7):1922-1924. https://doi.org/10.1111/ajt.15920

49. Hammami MB, Garibaldi B, Shah P, et al. Clinical course of COVID-19 in a liver transplant recipient on hemodialysis and response to tocilizumab: a case report. Am J Transplant. 2020;20(8):2254-2259. https://doi.org/10.1111/ajt.15985

50. Thammathiwat T, Tungsang S, Thiankanon K, et al. A case of successful treatment of severe COVID-19 pneumonia with favipiravir and tocilizumab in post-kidney transplant recipient. Transpl Infect Dis. 2020;22(5):e13377. https://doi.org/10.1111/tid.13377

51. Chen A, Konala VM, Gayam V, Naramala S, Adapa S. Coronavirus disease 2019 (COVID-19) in a renal transplant patient. Cureus. 2020;12(5):e8038. https://doi.org/10.7759/cureus.8038

52. Devresse A, Belkhir L, Vo B, et al. COVID-19 infection in kidney transplant recipients: a single-center case series of 22 cases from
